Regulus Therapeutics traded at $1.72 this Wednesday August 17th, decreasing $0 or 0 percent since the previous trading session. Looking back, over the last four weeks, Regulus Therapeutics lost 17.31 percent. Over the last 12 months, its price rose by 152.83 percent. Looking ahead, we forecast Regulus Therapeutics to be priced at 1.67 by the end of this quarter and at 1.54 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,864.00 20.00 0.52% 5.20%
Alnylam Pharmaceuticals 223.13 -5.02 -2.20% 12.96%
AstraZeneca 10,990.00 -12.00 -0.11% 25.80%
Astrazeneca 66.42 -0.32 -0.48% 11.74%
Biogen 217.58 -2.06 -0.94% -36.36%
Celldex Therapeutics 36.73 -0.59 -1.58% -17.76%
Gilead Sciences 66.02 -0.31 -0.47% -7.88%
GlaxoSmithKline 1,410.40 -5.00 -0.35% -6.82%
Intercept Pharmaceuticals 18.73 0.66 3.65% 31.72%
Incyte Corp 73.86 -1.10 -1.47% -0.91%
Ionis Pharmaceuticals 43.88 -0.44 -0.99% 15.38%
Ligand Pharmaceuticals 106.04 -1.52 -1.41% 0.70%
Lexicon Pharmaceuticals 3.06 -0.22 -6.71% -10.00%
Merck & Co 91.04 0.45 0.50% 17.03%
Omeros 6.63 0.09 1.38% -54.37%
Regulus Therapeutics 1.72 0 0% 152.83%
Sangamo BioSciences 5.89 -0.20 -3.28% -37.47%
Sanofi 42.18 -2.63 -5.87% -19.87%
Spectrum Pharmaceuticals 1.23 -0.18 -12.77% -44.34%
Immunic Inc. 5.02 -0.07 -1.38% -47.27%
Intrexon 2.28 -0.13 -5.39% -60.42%

Indexes Price Day Year
USND 12938 -164.43 -1.25% -10.93%
US2000 1987 -33.22 -1.64% -7.94%

Regulus Therapeutics
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases. Its product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a kidney disease. The Company completed Phase I multiple-ascending dose (MAD) clinical trial. RGLS4326, an anti-miR targeting miR-17, is for the treatment of autosomal dominant polycystic kidney disease (ADPKD). It is in Phase I clinical trial. The Company’s pre-clinical pipeline candidates include RGLS5579 and anti-miR-132. RGLS5579 is developing for the treatment of Glioblastoma and anti-miR-132 is developing for the treatment of non-alcoholic steatohepatitis. Its developing two undisclosed products under Cell Therapies program and Hepatitis B virus program.